Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...
Why Prime Medicine Stock Was Climbing Higher This Week
Prime's encouraging news came on Tuesday when the company announced it had launched a preclinical program aimed at treating alpha-1 antitrypsin deficiency (AATD). This is a genetic disorder caused by ...
Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The move up comes as the S&P 500 and Nasdaq Composite gained ...
BioWorld3d
Prime Medicine announces new α1-antitrypsin deficiency program
Prime Medicine Inc. has announced its new preclinical program for the treatment of α1-antitrypsin deficiency (AATD). The ...
Prime Medicine, Inc.: Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...
Prime sets sights on liver, lung disease as next target for its gene editing tech
The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...